Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: FirstWord Group | PRODUCT CODE: 1355373

Cover Image

PUBLISHER: FirstWord Group | PRODUCT CODE: 1355373

Gastric Cancer - KOL Insight

PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Multi User License (PDF)
USD 39950

Add to Cart

Why are KOLs encouraged by trial results of Astellas/Ganymed's pipeline anti-claudin 18.2 mAb zolbetuximab and in what settings do they see it delivering value? What safety concerns do experts express that could limit the first-line prospects of AstraZeneca/Daiichi Sankyo's Enhertu? Could Zymeworks' IgG1 bi-specific mAb Zanidatamab displace trastuzumab/pembrolizumab/chemotherapy? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Marketed treatments

  • Chemotherapy regimens and current treatment trends
    • Herceptin (trastuzumab; Roche)
    • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
    • Cyramza (ramucirumab; Lilly)
    • Key insights summary
    • Keytruda (pembrolizumab; Merck & Co.)
    • Nivolumab (Opdivo; BMS/Ono)

Late-stage pipeline programmes

  • Immunotherapies
    • Durvalumab (Imfinzi; AstraZeneca)
    • Sintilimab (Tyvyt; Innovent Biologics/ Lilly)
    • Tislelizumab (BGB-A317; BeiGene/Novartis)
    • Avelumab (Bavencio; Merck Group/Pfizer)
    • Atezolizumab (Tecentriq; Roche)
  • Targeted biologic therapies
    • Zolbetuximab (IMAB362/claudiximab; Astellas/Ganymed)
    • Margetuximab/retifanlimab/tebotelimab (MacroGenics/Incyte)
    • Bemarituzumab (Five Prime Therapeutics/Amgen)
    • Zanidatamab (ZW25; Zymeworks)
    • Evorpacept (ALX Oncology)
    • Catumaxomab (Removab; LintonPharm)
    • ARX788 (Ambrx/Zhejiang Medicine)
  • Targeted oral therapies
    • Stivarga (regorafenib; Bayer)
  • PARP inhibitors
    • Olaparib (Lynparza; AstraZeneca); pamiparib (BeiGene)
  • Next-generation therapies
    • Sirexatamab (DKN-01; Leap Therapeutics/BeiGene)

Future treatment trends

  • Cell therapies and gastric cancer vaccines
    • Other promising pipeline technologies for gastric cancer

Appendix

  • KOL details
    • KOLs from the USA
    • KOLs from Europe

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Marketed treatments

  • Chemotherapy regimens and current treatment trends
    • Herceptin (trastuzumab; Roche)
    • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
    • Cyramza (ramucirumab; Lilly)
    • Key insights summary
    • Keytruda (pembrolizumab; Merck & Co.)
    • Nivolumab (Opdivo; BMS/Ono)

Late-stage pipeline programmes

  • Immunotherapies
    • Durvalumab (Imfinzi; AstraZeneca)
    • Sintilimab (Tyvyt; Innovent Biologics/ Lilly)
    • Tislelizumab (BGB-A317; BeiGene/Novartis)
    • Avelumab (Bavencio; Merck Group/Pfizer)
    • Atezolizumab (Tecentriq; Roche)
  • Targeted biologic therapies
    • Zolbetuximab (IMAB362/claudiximab; Astellas/Ganymed)
    • Margetuximab/retifanlimab/tebotelimab (MacroGenics/Incyte)
    • Bemarituzumab (Five Prime Therapeutics/Amgen)
    • Zanidatamab (ZW25; Zymeworks)
    • Evorpacept (ALX Oncology)
    • Catumaxomab (Removab; LintonPharm)
    • ARX788 (Ambrx/Zhejiang Medicine)
  • Targeted oral therapies
    • Stivarga (regorafenib; Bayer)
  • PARP inhibitors
    • Olaparib (Lynparza; AstraZeneca); pamiparib (BeiGene)
  • Next-generation therapies
    • Sirexatamab (DKN-01; Leap Therapeutics/BeiGene)

Future treatment trends

  • Cell therapies and gastric cancer vaccines
    • Other promising pipeline technologies for gastric cancer

Appendix

  • KOL details
    • KOLs from the USA
    • KOLs from Europe
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!